Phase II clinical trial - Appareil Digestif
REGIRI (PRODIGE 58)
Appareil Digestif
Essai clinique fermé
Public cible
Adulte
A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas
Description de l'essai
Comparative interventional prospective phase II, randomised, open-label, multicentric trial comparing the combination of regorafenib and irinotecan (REGIRI) to irinotecan alone (IRI) as second-line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.
Liens utiles